Trials / Unknown
UnknownNCT04691349
CAR-T for r/r Malignant Tumors in Children
Chimeric Antigen Receptor T Cells Therapy for r/r Malignant Tumors in Children
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Industry
- Sex
- All
- Age
- 3 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a clinical study of CAR-T treatment of patients with relapsed/refractory malignant tumors in children. The purpose is to evaluate the safety and effectiveness of chimeric antigen receptor T cells in the treatment of relapsed/refractory malignant tumors in children.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CAR-T | The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. |
Timeline
- Start date
- 2020-09-27
- Primary completion
- 2021-01-26
- Completion
- 2021-09-26
- First posted
- 2020-12-31
- Last updated
- 2021-01-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04691349. Inclusion in this directory is not an endorsement.